140 related articles for article (PubMed ID: 30276144)
1. Impact of Omega-3 Supplementation on High Sensitive C-Reactive Protein Level and 30-Day Major Adverse Cardiac Events After the Implementation of Coronary Stent in Patients with Chronic Kidney Disease: A Randomized Clinical Study.
Foroughinia F; Movahed Nouri B; Kojuri J; Ostovan MA
Adv Pharm Bull; 2018 Aug; 8(3):471-478. PubMed ID: 30276144
[No Abstract] [Full Text] [Related]
2. Effect of Pretreatment with Omega-3 Supplement on Cardiac Necrosis Markers in Chronic Kidney Disease Patients Undergoing Elective Percutaneous Coronary Intervention.
Foroughinia F; Foroozmehr M
J Res Pharm Pract; 2017; 6(2):94-99. PubMed ID: 28616432
[TBL] [Abstract][Full Text] [Related]
3. Effect of rosuvastatin dose-loading on serum sLox-1, hs-CRP, and postoperative prognosis in diabetic patients with acute coronary syndromes undergoing selected percutaneous coronary intervention (PCI).
Jiao Y; Hu F; Zhang Z; Gong K; Sun X; Li A; Liu N
Int J Clin Exp Med; 2015; 8(11):21565-71. PubMed ID: 26885106
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Loading-Dose Rosuvastatin Therapy in Elderly Patients with Acute Coronary Syndromes Undergoing Elective Percutaneous Coronary Intervention.
Jiao Y; Hu F; Zhang Z; Gong K; Sun X; Li A; Liu N
Clin Drug Investig; 2015 Dec; 35(12):777-84. PubMed ID: 26387028
[TBL] [Abstract][Full Text] [Related]
5. Protection from procedural myocardial injury by omega-3 polyunsaturated fatty acids (PUFAs): is related with lower levels of creatine kinase-MB (CK-MB) and troponin I?
Foroughinia F; Salamzadeh J; Namazi MH
Cardiovasc Ther; 2013 Oct; 31(5):268-73. PubMed ID: 23134549
[TBL] [Abstract][Full Text] [Related]
6. Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial.
Stone GW; Généreux P; Harrington RA; White HD; Gibson CM; Steg PG; Hamm CW; Mahaffey KW; Price MJ; Prats J; Deliargyris EN; Bhatt DL
Eur Heart J; 2018 Dec; 39(46):4112-4121. PubMed ID: 30203006
[TBL] [Abstract][Full Text] [Related]
7. Changes of High Sensitivity C-Reactive Protein During Clopidogrel Therapy in Patients Undergoing Percutaneous Coronary Intervention.
Hajsadeghi S; Chitsazan M; Chitsazan M; Salehi N; Amin A; Maleki M; Babaali N; Abdi S; Mohsenian M
Res Cardiovasc Med; 2016 Feb; 5(1):e28997. PubMed ID: 26889454
[TBL] [Abstract][Full Text] [Related]
8. High-sensitivity cardiac troponin decrease after percutaneous coronary intervention in patients with stable coronary artery disease.
Hamaya R; Horie T; Yonetsu T; Sugano A; Kanaji Y; Usui E; Hoshino M; Yamaguchi M; Ohya H; Sumino Y; Hada M; Hirano H; Kanno Y; Yuki H; Hirao K; Kakuta T
Heart Vessels; 2019 Jun; 34(6):948-956. PubMed ID: 30600349
[TBL] [Abstract][Full Text] [Related]
9. [Short-term outcomes of triple antiplatelet therapy after percutaneous coronary intervention].
Han YL; Su QF; Li Y; Wang SL; Jing QM; Ma YY; Wang ZL; Wang DM; Luan B
Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(16):1093-6. PubMed ID: 16796832
[TBL] [Abstract][Full Text] [Related]
10. Combined impact of residual inflammatory risk and chronic kidney disease on long-term clinical outcomes in patients undergoing percutaneous coronary intervention.
Nishio R; Dohi T; Takeuchi M; Takahashi N; Endo H; Doi S; Okai I; Iwata H; Okazaki S; Miyauchi K; Daida H; Minamino T
J Cardiol; 2022 Apr; 79(4):509-514. PubMed ID: 34799214
[TBL] [Abstract][Full Text] [Related]
11. Independent and Combined Effects of Serum Albumin and C-Reactive Protein on Long-Term Outcomes of Patients Undergoing Percutaneous Coronary Intervention.
Wada H; Dohi T; Miyauchi K; Doi S; Naito R; Konishi H; Tsuboi S; Ogita M; Kasai T; Okazaki S; Isoda K; Suwa S; Daida H
Circ J; 2017 Aug; 81(9):1293-1300. PubMed ID: 28428450
[TBL] [Abstract][Full Text] [Related]
12. Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes.
Wang Z; Dai H; Xing M; Yu Z; Lin X; Wang S; Zhang J; Hou F; Ma Y; Ren Y; Tan K; Wang Y; Ge Z
J Cardiovasc Pharmacol Ther; 2013 Jul; 18(4):327-33. PubMed ID: 23364255
[TBL] [Abstract][Full Text] [Related]
13. Omega-3 Supplementation in the Prevention of Contrast Induced Nephropathy in Patients Undergoing Elective Percutaneous Coronary Intervention: A Randomized Placebo-Controlled Trial.
Foroughinia F; Mirjalili M; Mirzaei E; Oboodi A
Adv Pharm Bull; 2019 Jun; 9(2):307-313. PubMed ID: 31380258
[No Abstract] [Full Text] [Related]
14. Impact of Supplementation with Omega-3 in the Prevention of Contrast-Induced Nephropathy Following Elective Percutaneous Coronary Intervention in Patients with Chronic Kidney Disease: A Randomized Placebo-Controlled Trial.
Foroughinia F; Rohani Rad E
Int J Prev Med; 2020; 11():193. PubMed ID: 33815717
[TBL] [Abstract][Full Text] [Related]
15. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Steinhubl SR; Berger PB; Mann JT; Fry ET; DeLago A; Wilmer C; Topol EJ;
JAMA; 2002 Nov; 288(19):2411-20. PubMed ID: 12435254
[TBL] [Abstract][Full Text] [Related]
16. The Potential Effect of Intravenous Calcitriol on the Ischemia-Reperfusion Process and Inflammatory Biomarkers in Patients Following Percutaneous Coronary Intervention (PCI).
Dastan F; Salamzadeh J; Alipour-Parsa S; Sharif Kashani B; Hashempour MM
Iran J Pharm Res; 2019; 18(Suppl1):282-290. PubMed ID: 32802107
[TBL] [Abstract][Full Text] [Related]
17. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.
Gajos G; Rostoff P; Undas A; Piwowarska W
J Am Coll Cardiol; 2010 Apr; 55(16):1671-8. PubMed ID: 20394870
[TBL] [Abstract][Full Text] [Related]
18. Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial.
Crimi G; Leonardi S; Costa F; Adamo M; Ariotti S; Valgimigli M
Int J Cardiol; 2016 Jun; 212():110-7. PubMed ID: 27038714
[TBL] [Abstract][Full Text] [Related]
19. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.
Liu T; Xie Y; Zhou YJ; Li YP; Ma HY; Guo YH; Liu YY; Zhao YX; Shi DM
Chin Med J (Engl); 2009 Aug; 122(15):1732-7. PubMed ID: 19781316
[TBL] [Abstract][Full Text] [Related]
20. Impact of Chronic Kidney Disease on Cardiovascular and Renal Events in Patients Undergoing Percutaneous Coronary Intervention with Everolimus-Eluting Stent: Risk Stratification with C-Reactive Protein.
Dan K; Miyoshi T; Nakahama M; Mizuno T; Kagawa K; Naito Y; Kawada S; Ito H
Cardiorenal Med; 2018; 8(2):151-159. PubMed ID: 29617004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
